LLY

1,084.9

+1%↑

JNJ

231.61

+0.29%↑

ABBV

214.93

+1.26%↑

UNH

381.61

+0.56%↑

AZN

186.94

-0.13%↓

LLY

1,084.9

+1%↑

JNJ

231.61

+0.29%↑

ABBV

214.93

+1.26%↑

UNH

381.61

+0.56%↑

AZN

186.94

-0.13%↓

LLY

1,084.9

+1%↑

JNJ

231.61

+0.29%↑

ABBV

214.93

+1.26%↑

UNH

381.61

+0.56%↑

AZN

186.94

-0.13%↓

LLY

1,084.9

+1%↑

JNJ

231.61

+0.29%↑

ABBV

214.93

+1.26%↑

UNH

381.61

+0.56%↑

AZN

186.94

-0.13%↓

LLY

1,084.9

+1%↑

JNJ

231.61

+0.29%↑

ABBV

214.93

+1.26%↑

UNH

381.61

+0.56%↑

AZN

186.94

-0.13%↓

Home・Aandelen Lijst・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Open

SectorGezondheidszorg

31.29 -0.03

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

31.26

Max

31.34

Belangrijke statistieken
By Trading Economics
Inkomsten	11M 64M
Verkoop	-3.2M 149M
K/W Sectorgemiddelde	18.052 49.701
EPS	0.79
Winstmarge	42.663
Werknemers	182
EBITDA	2M 83M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+5.65% upside

Dividenden
By Dow Jones
Volgende Winsten	5 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	281M 3.8B
Vorige openingsprijs	31.32
Vorige sluitingsprijs	31.29

Nieuwssentiment

By Acuity

50%

154 / 344 Rangschikking in Healthcare

Catalyst Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

26 mei 2026, 16:52 UTC

Belangrijke Nieuwsgebeurtenissen

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26 mei 2026, 23:57 UTC

Winsten

Sociedad Quimica 1Q Rev $1.76B >SQM

26 mei 2026, 23:57 UTC

Winsten

Sociedad Quimica 1Q EPS $1.28 >SQM

26 mei 2026, 23:48 UTC

Marktinformatie

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26 mei 2026, 21:54 UTC

Winsten

Webco Industries 3Q EPS $11.61 >WEBC

26 mei 2026, 21:54 UTC

Winsten

Webco Industries 3Q Sales $179.6M >WEBC

26 mei 2026, 21:48 UTC

Marktinformatie

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26 mei 2026, 21:00 UTC

Marktinformatie

ESG Roundup: Market Talk

26 mei 2026, 20:58 UTC

Acquisities, Fusies, Overnames

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26 mei 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

26 mei 2026, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

26 mei 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

26 mei 2026, 19:22 UTC

Marktinformatie

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26 mei 2026, 19:17 UTC

Marktinformatie

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26 mei 2026, 18:56 UTC

Marktinformatie

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26 mei 2026, 18:03 UTC

Marktinformatie

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26 mei 2026, 17:42 UTC

Marktinformatie

Grains Await Fresh Trading Catalyst -- Market Talk

26 mei 2026, 17:33 UTC

Marktinformatie

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26 mei 2026, 17:21 UTC

Marktinformatie

Canada Faces a Labor Market Squeeze -- Market Talk

26 mei 2026, 16:52 UTC

Marktinformatie

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26 mei 2026, 16:43 UTC

Marktinformatie

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26 mei 2026, 16:24 UTC

Marktinformatie

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26 mei 2026, 16:21 UTC

Marktinformatie

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26 mei 2026, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

26 mei 2026, 16:20 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

26 mei 2026, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

26 mei 2026, 16:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Auto & Transport Roundup: Market Talk

26 mei 2026, 16:16 UTC

Marktinformatie

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26 mei 2026, 16:01 UTC

Marktinformatie

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26 mei 2026, 15:21 UTC

Marktinformatie

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Peer Vergelijking

Prijswijziging

Catalyst Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

5.65% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 33.1 USD 5.65%

Hoogste 35 USD

Laagste 31.5 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Catalyst Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

Buy

Hold

Sell

Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan Catalyst Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

154 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.